ASCO 2021: Summary Overview and Outlook 1

The annual meeting of the American Society of Clinical Oncology ( ASCO ) will be held from June 4 to 8, 2021.

The annual meeting of the American Society of Clinical Oncology ( ASCO ) will be held from June 4 to 8, 2021.

The results of Sanofi and Sloan Kettering’s ER+/HER2 treatment for breast cancer are encouraging: Sanofi’s Amcenestrant combination therapy shows an ORR of 34% for breast cancer patients, Sanofi’s and Sloan Kettering’s ER+/ The results of HER2 treatment of breast cancer are encouraging: Sanofi’s Amcenestrant combination therapy shows an ORR of 34% for breast cancer patients

Sanofi and Memorial Sloan Kettering Cancer Center will present the first phase data of the AMEERA-1 experimental cen agent.

"Sloan Kettering Memorial Cancer Center oncologist Sarat Chandarlapaty (Sarat Chandarlapaty) said: "These early clinical data show that the combination with palbociclib has achieved encouraging anti-tumor activity.

"These early clinical data show that the combination with palbociclib has achieved encouraging anti-tumor activity.

palbociclib palbociclib has an objective response rate (ORR) of 34% for its drug acuity agent and a 34% clinical benefit rate (CBR) of 74% for its drug acuity agent .

Incyte must give at least 10 oral reports, Incyte must give at least 10 oral reports

Incyte said it plans to show a series of posters to ASCO from its oncology channel.

Steven Stein, Chief Medical Officer of Incyte, said: “We look forward to presenting data from Incyte’s various oncology products and partner programs at this year’s ASCO annual meeting.

Exelixis conducted 20 oral reports on cabozantinib

Exelixis be Cabozantinib ( cabozantinib ) of 20 oral reports were Cabozantinib (Exelixis cabozantinib report) of 20 oral cabozantinib

In the company's first quarter financial report on May 6, Exelixis announced that its cabozantinib will be the subject of 20 speeches.

The company also demonstrated from Cabozantinib ( cabozantinib ) data for the third phase of the study of thyroid cancer.

Cabozantinib ( cabozantinib ) Cabozantinib ( cabozantinib ) cabozantinib

The company previously reported key data for 2020, showing that the tyrosine kinase inhibitor Cabometyx reduces the risk of disease progression or death by 78%, which is its primary endpoint.

The new data will detail long-term data-the median time for placebo patients is 1.

The new data will detail long-term data-the median time for placebo patients is 1.

AstraZeneca wants to redefine cancer treatment AstraZeneca wants to redefine cancer treatment

AstraZeneca plans to display more than 100 abstracts from its oncology portfolio, including 21 approved and under development drugs.

Dave Fredrickson, Executive Vice President of the Oncology Business Unit, said: "Our data at ASCO this year shows that we are unwavering in our determination to revolutionize cancer treatment and strengthen our expertise in lung and breast cancer as well as Leadership in the field of hematology.

Read more: ASCO 2021: Summary Overview and Outlook 2

ASCO 2021: Summary Overview and Outlook 2

Leave a message here